GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (NAS:FBLG) » Definitions » Short-Term Debt

FibroBiologics (FibroBiologics) Short-Term Debt : $0.46 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is FibroBiologics Short-Term Debt?

FibroBiologics's Short-Term Debt for the quarter that ended in Mar. 2024 was $0.46 Mil.

FibroBiologics's quarterly Short-Term Debt stayed the same from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($0.46 Mil).

FibroBiologics's annual Short-Term Debt increased from Dec. 2021 ($1.30 Mil) to Dec. 2022 ($5.45 Mil) but then declined from Dec. 2022 ($5.45 Mil) to Dec. 2023 ($0.00 Mil).


FibroBiologics Short-Term Debt Historical Data

The historical data trend for FibroBiologics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroBiologics Short-Term Debt Chart

FibroBiologics Annual Data
Trend Dec21 Dec22 Dec23
Short-Term Debt
1.30 5.45 -

FibroBiologics Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only - - - - 0.46

FibroBiologics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


FibroBiologics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of FibroBiologics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroBiologics (FibroBiologics) Business Description

Comparable Companies
Traded in Other Exchanges
Address
455 E. Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598
FibroBiologics Inc is an early-stage, cell therapy company. Its primary focus is the initiation and progression of preclinical studies and clinical-stage FDA trials related to fibroblast treatments for Degenerative Disc Disease, Multiple Sclerosis, Cancer, Wound Healing, and other diseases.

FibroBiologics (FibroBiologics) Headlines